Compare alternative providers
Alternatives to Freya Meds
Freya Meds grades C (58.6/100), #416 of 541 on our scorecard. Start with a featured alternative, then explore providers with similar listed prices and treatment options. Compare their scores and terms below.
You're comparing against
Freya Meds →Featured alternative
CoreAge Rx scores 89.5/100. Check the price conditions and care terms against Freya Meds.
Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
More options to compare
iThriveMD is a longevity and metabolic-health clinic (physical locations plus telehealth) offering compounded GLP-1 weight loss — semaglutide (from $299/mo) and tirzepatide (from $399/mo), plus microdosing tirzepatide programs — alongside hormone therapy (HRT/TRT), NAD+, peptides, IV therapy, sexual health, and diagnostic lab testing.
Fella Health is a medication weight loss program built specifically for men, offering compounded GLP-1 treatments (semaglutide and tirzepatide) plus free 1:1 health coaching, board-certified clinician care, and a 6-month money-back guarantee.
Vyora Wellness offers compounded semaglutide ($299/mo) and compounded tirzepatide ($399/mo) as 4-week subscription plans.
Prime Health (joinprimehealth.com) is a LegitScript-certified GLP-1 telehealth platform offering compounded semaglutide and tirzepatide for weight loss.
tru Weight Loss (truhealthnow) is a physician-directed telehealth program prescribing compounded semaglutide and tirzepatide, shipped from US-licensed compounding pharmacies.
The 6 alternatives above offer other options to compare with Freya Meds. Every provider we grade — all 541 of them — is scored on the same six factors: browse every graded provider.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.